- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02313376
Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes
Trial to Assess the Safety, Attenuation and Immunogenicity of Genetically-attenuated p52-/p36-/sap1- Plasmodium Falciparum Parasites (GAP3KO) Administered Via Infected Anopheles Stephensi Mosquitoes to Malaria-Naïve Adults
Study Overview
Detailed Description
This single arm, open-label, phase 1 safety study is designed to evaluate the safety and tolerability of a genetically attenuated P. falciparum (GAP3KO) that arrests early in the liver stage of the parasite life cycle. The study will also confirm the attenuation of the GAP3KO parasites using peripheral blood smears. The secondary objectives of the study are to evaluate the humoral immune responses to GAP3KO.
A total of 10 healthy, malaria-naïve adult subjects will be enrolled to receive GAP3KO via the bite of 150-200 GAP3K0-infected A. stephensi mosquitoes under controlled conditions. Subjects will be evaluated for safety, reactogenicity, and signs and symptoms of malaria to confirm attenuation for 28 days, including monitoring in a hotel setting 8-18 days post GAP 3KO administration.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Seattle Biomedical Research Institute Malaria Clinical Trial Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Good general health
- No hematologic, hepatic, or renal disease
- Weight greater than 50 kg
- Assessment of Understanding completed and passed prior to enrollment
- Availability and reliable access to trial center
- Females must use two forms of pregnancy prevention
Exclusion Criteria:
- Recent (within 6 months) or planned travel to malaria endemic area
- History of confirmed malaria diagnosis
Anticipated use of the following:
- Investigational malaria vaccine at any time
- Malaria chemoprophylaxis within 6 months
- Chronic systemic immunosuppressive medications within 6 months
- Blood products or immunoglobulin within 120 days
- Systemic antibiotics with antimalarial effects within 30 days
- Investigational product or vaccine within 30 days
- Live vaccine within 28 days; killed vaccine within 14 days of GAP3KO
- Medications known to significantly interact with chloroquine or Malarone
History of:
- Sickle cell trait or other hemoglobinopathies
- Splenectomy or functional asplenia
- Systemic anaphylaxis
- Severe allergic reaction to mosquito bites or malaria treatment drugs
- History of chronic or active neurologic disease
- Cardiac disease or stroke
- Clinically significant medical condition, abnormal lab results
- Clinically significant abnormal ECG
- Moderate or high risk for coronary heart disease
- Acute illness
- Pregnant or nursing female
- HIV, Hepatitis B, or Hepatitis C
- Psychiatric condition that precludes compliance with the protocol
- Suspected or known alcohol or drug abuse
- Staff with direct involvement in conduct of the study or GAP activities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GAP3KO
|
GAP3KO administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes under controlled conditions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety assessed by frequency of AEs, SAEs, and patent parasitemia via peripheral blood smear
Time Frame: 28 Days
|
28 Days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CSP antibody titer
Time Frame: 28 days
|
28 days
|
Percent inhibition of in vitro sporozoite
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MC-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Syamsudin Abdillah,Ph.D, Pharm DCipto Mangunkusumo Hospital; PT Natura Nuswantara NirmalaCompletedInfections | Malaria | Malaria, Vivax | Uncomplicated Malaria | Malaria,Falciparum | Uncomplicated Plasmodium FalciparumIndonesia
Clinical Trials on GAP3KO
-
National Institute of Allergy and Infectious Diseases...CompletedPlasmodium Falciparum InfectionUnited States